Transaction #33842 · Form 4 · 0001796226-26-000002
REGENERON PHARMACEUTICALS, INC. · Exercise / conversion · Common Stock
REGENERON PHARMACEUTICALS, INC. · Transacted October 13, 2026 · Filed October 15, 2026
What does this filing report?
An SEC Form 4 filing for REGENERON PHARMACEUTICALS, INC. records an exercise / conversion involving Common Stock on October 13, 2026. The reported quantity was 17,000. The filing date is October 15, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0000872589
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 17,000
- Reported price
- 381.92
- Reference value
- 6,492,640
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 64,833
- Ownership description
- Not reported
- SEC acceptance time
- Oct 15, 2026, 4:02 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- MURPHY ANDREW J ↗
Co-Chief Scientific Officer
CIK 0001796226
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
REGN · Nasdaq · linked security
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026.
- F2
- Represents volume-weighted average price of sales of 14 shares of Company stock on October 14, 2026 at prices ranging from $759.94 to $759.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F3
- Represents volume-weighted average price of sales of 74 shares of Company stock on October 14, 2026 at prices ranging from $760.28 to $760.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F4
- Represents volume-weighted average price of sales of 27 shares of Company stock on October 14, 2026 at prices ranging from $761.01 to $761.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F5
- Represents volume-weighted average price of sales of 25 shares of Company stock on October 14, 2026 at prices ranging from $763.62 to $763.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F6
- Represents volume-weighted average price of sales of 219 shares of Company stock on October 14, 2026 at prices ranging from $764.04 to $764.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F7
- Represents volume-weighted average price of sales of 271 shares of Company stock on October 14, 2026 at prices ranging from $765.11 to $765.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F8
- Represents volume-weighted average price of sales of 279 shares of Company stock on October 14, 2026 at prices ranging from $766.00 to $766.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F9
- Represents volume-weighted average price of sales of 192 shares of Company stock on October 14, 2026 at prices ranging from $767.10 to $767.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F10
- Represents volume-weighted average price of sales of 105 shares of Company stock on October 14, 2026 at prices ranging from $768.15 to $768.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F11
- Represents volume-weighted average price of sales of 127 shares of Company stock on October 14, 2026 at prices ranging from $769.15 to $769.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F12
- Represents volume-weighted average price of sales of 283 shares of Company stock on October 14, 2026 at prices ranging from $771.04 to $771.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F13
- Represents volume-weighted average price of sales of 211 shares of Company stock on October 14, 2026 at prices ranging from $772.06 to $772.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F14
- Represents volume-weighted average price of sales of 224 shares of Company stock on October 14, 2026 at prices ranging from $773.14 to $773.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F15
- Represents volume-weighted average price of sales of 121 shares of Company stock on October 14, 2026 at prices ranging from $774.11 to $774.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F16
- Represents volume-weighted average price of sales of 376 shares of Company stock on October 14, 2026 at prices ranging from $775.14 to $775.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F17
- Represents volume-weighted average price of sales of 66 shares of Company stock on October 14, 2026 at prices ranging from $776.00 to $776.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F18
- Represents volume-weighted average price of sales of 38 shares of Company stock on October 14, 2026 at prices ranging from $777.51 to $777.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F19
- Represents volume-weighted average price of sales of 454 shares of Company stock on October 14, 2026 at prices ranging from $778.05 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F20
- Represents volume-weighted average price of sales of 380 shares of Company stock on October 14, 2026 at prices ranging from $779.00 to $779.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F21
- Represents volume-weighted average price of sales of 463 shares of Company stock on October 14, 2026 at prices ranging from $780.06 to $780.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F22
- Represents volume-weighted average price of sales of 50 shares of Company stock on October 14, 2026 at prices ranging from $781.05 to $781.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price.
- F23
- The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.